Provided by Tiger Trade Technology Pte. Ltd.

PELTHOS THERAPEUTICS INC

20.50
0.0000
Post-market: 20.500.00000.00%16:10 EDT
Volume:45.02K
Turnover:943.38K
Market Cap:78.48M
PE:-0.78
High:21.16
Open:20.80
Low:20.50
Close:20.50
52wk High:37.50
52wk Low:18.19
Shares:3.83M
Float Shares:1.07M
Volume Ratio:1.02
T/O Rate:4.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-26.3603
EPS(LYR):-23.0359
ROE:-333.84%
ROA:-49.98%
PB:-52.29
PE(LYR):-0.89

Loading ...

Lake Street Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)

TIPRANKS
·
Oct 06

OS Therapies Names Kerry Clem Chief Commercial Officer

Reuters
·
Oct 06

Pelthos Therapeutics Hosts Annual Shareholder Meeting, Quorum Present

Reuters
·
Oct 02

OS Therapies Names Kerry Clem Chief Commercial Officer

Reuters
·
Oct 01

Analysts Offer Insights on NA Companies: Flex (FLEX), Howard Hughes Holdings (HHH) and Pelthos Therapeutics (PTHS)

TIPRANKS
·
Sep 28

Analysts Offer Insights on NA Companies: Pelthos Therapeutics (PTHS) and X-Energy, Inc. Class A (XE)

TIPRANKS
·
Sep 08

Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)

TIPRANKS
·
Aug 24

Pelthos Therapeutics Announces Annual Shareholder Meeting

Reuters
·
Aug 19

Scienture Q2 Revenue Surges on Rezenopy Launch

Reuters
·
Aug 14

Pelthos Therapeutics (PTHS) Gets a Buy from Alliance Global Partners

TIPRANKS
·
Aug 14

Pelthos Therapeutics Falls as Co Says Will Restate Q1 Financial Statements

Reuters
·
Aug 13

Biofrontera Q2 Revenue Rises on Higher Volume, Pricing

Reuters
·
Aug 13

Pelthos Therapeutics Posts Investor Deck Outlining Dermatology Portfolio Strategy Centered on Zelsuvmi Launch, Xepi and Xeglyze Additions

Reuters
·
Aug 13

Pelthos Therapeutics Q2 Revenue Rises on Zelsuvmi Adoption

Reuters
·
Aug 13

Pelthos Q2 FY26 Net Loss Narrows to $23.42 Million; Net Product Revenue Climbs 45% to $15.4 Million

Reuters
·
Aug 13

Pelthos Therapeutics Q2 Net Income USD -23.417 Million

THOMSON REUTERS
·
Aug 13

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 13

Pelthos Therapeutics Restates Q1 2026 Net Loss to USD 25.07 Million

Reuters
·
Aug 13

Pelthos Restates Q1 Results After ASC 820 Error Lifts Convertible Debt Fair Value by $15.8 Million

Reuters
·
Aug 13

Pelthos Therapeutics - Restatement Will not Impact Liquidity or Cash Position for Quarter Ended March 31, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 13